메뉴 건너뛰기




Volumn 39, Issue 10, 2017, Pages 2024-2037

Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds

Author keywords

confounder in clinical research; failed clinical trial; incretin therapy; MK 3102; oral antihyperglycemic agent; patient nonadherence to the protocol

Indexed keywords

AMYLASE; CREATINE KINASE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; OMARIGLIPTIN; PLACEBO; TRIACYLGLYCEROL LIPASE; 2-(2,5-DIFLUOROPHENYL)-5-(2-(METHYLSULFONYL)-2,6-DIHYDROPYRROLO(3,4-C)PYRAZOL-5(4H)-YL)TETRAHYDRO-2H-PYRAN-3-AMINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FUSED HETEROCYCLIC RINGS; GLYCOSYLATED HEMOGLOBIN; PYRAN DERIVATIVE;

EID: 85029481797     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2017.08.009     Document Type: Article
Times cited : (6)

References (11)
  • 1
    • 84899522115 scopus 로고    scopus 로고
    • Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes
    • Biftu, T., Sinha-Roy, R., Chen, P., et al. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem 57 (2014), 3205–3212.
    • (2014) J Med Chem , vol.57 , pp. 3205-3212
    • Biftu, T.1    Sinha-Roy, R.2    Chen, P.3
  • 2
    • 84924042029 scopus 로고    scopus 로고
    • Effect of omarigliptin, a novel once-weekly DPP-4 inhibitor, in Japanese patients with type 2 diabetes: a placebo- and sitagliptin-controlled trial
    • Gantz, I., Okamoto, T., Ito, Y., et al. Effect of omarigliptin, a novel once-weekly DPP-4 inhibitor, in Japanese patients with type 2 diabetes: a placebo- and sitagliptin-controlled trial. Diabetologia, 57, 2014, S55.
    • (2014) Diabetologia , vol.57 , pp. S55
    • Gantz, I.1    Okamoto, T.2    Ito, Y.3
  • 3
    • 85019792352 scopus 로고    scopus 로고
    • Omarigliptin, a once-weekly DPP-4 inhibitor, provides similar glycemic control to sitagliptin in patients with T2DM inadequately controlled on metformin
    • Gantz, I., Lai, E., Suryawanshi, S., et al. Omarigliptin, a once-weekly DPP-4 inhibitor, provides similar glycemic control to sitagliptin in patients with T2DM inadequately controlled on metformin. Diabetologia 58 (2015), S54–S55.
    • (2015) Diabetologia , vol.58 , pp. S54-S55
    • Gantz, I.1    Lai, E.2    Suryawanshi, S.3
  • 4
    • 0003244085 scopus 로고    scopus 로고
    • Longitudinal data analysis of continuous and discrete responses for pre-post designs
    • Liang, K.Y., Zeger, S.L., Longitudinal data analysis of continuous and discrete responses for pre-post designs. Indian J Statistics 62 (2000), 134–148.
    • (2000) Indian J Statistics , vol.62 , pp. 134-148
    • Liang, K.Y.1    Zeger, S.L.2
  • 5
    • 84962439676 scopus 로고    scopus 로고
    • Safety and efficacy of omarigliptin (MK-3102), a novel once-weekly DPP-4 inhibitor for the treatment of patients with type 2 diabetes
    • Sheu, W.H., Gantz, I., Chen, M., et al. Safety and efficacy of omarigliptin (MK-3102), a novel once-weekly DPP-4 inhibitor for the treatment of patients with type 2 diabetes. Diabetes Care 38 (2015), 2106–2114.
    • (2015) Diabetes Care , vol.38 , pp. 2106-2114
    • Sheu, W.H.1    Gantz, I.2    Chen, M.3
  • 6
    • 85010285221 scopus 로고    scopus 로고
    • Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
    • Goldenberg, R., Gantz, I., Andryuk, P.J., et al. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 19 (2017), 394–400.
    • (2017) Diabetes Obes Metab , vol.19 , pp. 394-400
    • Goldenberg, R.1    Gantz, I.2    Andryuk, P.J.3
  • 7
    • 85019808869 scopus 로고    scopus 로고
    • Omarigliptin, a once-weekly DPP-4 inhibitor, improves glycemic control in patients inadequately controlled on the combination of metformin and glimepiride
    • Lee, S.H., Gantz, I., Round, E., et al. Omarigliptin, a once-weekly DPP-4 inhibitor, improves glycemic control in patients inadequately controlled on the combination of metformin and glimepiride. Diabetes, 65, 2016, A50.
    • (2016) Diabetes , vol.65 , pp. A50
    • Lee, S.H.1    Gantz, I.2    Round, E.3
  • 8
    • 84946211125 scopus 로고    scopus 로고
    • Omarigliptin improves glycemic control and is well tolerated as add-on therapy to oral antihyperglycemic agents in Japanese patients with type 2 diabetes
    • Gantz, I., Okamoto, T., Sato, A., et al. Omarigliptin improves glycemic control and is well tolerated as add-on therapy to oral antihyperglycemic agents in Japanese patients with type 2 diabetes. Diabetes 64 (2015), A318–A319.
    • (2015) Diabetes , vol.64 , pp. A318-A319
    • Gantz, I.1    Okamoto, T.2    Sato, A.3
  • 9
    • 84892886983 scopus 로고    scopus 로고
    • Subversive subjects: rule-breaking and deception in clinical trials
    • Dresser, R., Subversive subjects: rule-breaking and deception in clinical trials. J Law Med Ethics 41 (2013), 829–840.
    • (2013) J Law Med Ethics , vol.41 , pp. 829-840
    • Dresser, R.1
  • 10
    • 0025250205 scopus 로고
    • Surreptitious drug use by patients in a panic disorder study
    • Clark, D.B., Taylor, C.B., Roth, W.T., et al. Surreptitious drug use by patients in a panic disorder study. Am J Psychiatry 147 (1990), 507–509.
    • (1990) Am J Psychiatry , vol.147 , pp. 507-509
    • Clark, D.B.1    Taylor, C.B.2    Roth, W.T.3
  • 11
    • 84889808445 scopus 로고    scopus 로고
    • Concealment and fabrication by experienced research subjects
    • Devine, E.G., Waters, M.E., Putnam, M., et al. Concealment and fabrication by experienced research subjects. Clin Trials 10 (2013), 935–948.
    • (2013) Clin Trials , vol.10 , pp. 935-948
    • Devine, E.G.1    Waters, M.E.2    Putnam, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.